Pro-Pharmaceuticals (PRW) Announces FDA Approves IND For Use of DAVANAT
More News related to PRW
- Pro-Pharmaceuticals (PRW) Anticipates Listing on Bulletin Board; Releases President and Chief Scientist
- Pro-Pharmaceuticals (PRW) Receives FDA IND Application for Use of DAVANAT(R)
- Pro-Pharmaceuticals (PRW) Announces FDA Approves IND For Use of DAVANAT
- Pro-Pharmaceuticals (PRW) Reports Positive Phase II Data of DAVANAT in Combination with 5-fluorouracil
- Pro-Pharmaceuticals (PRW) Receives Non-Compliance Notification From AMEX
More News related to FDA
- AspenBio Pharma (APPY) Reports Results from Interim Analysis for Ongoing Trial of AppyScore
- XenoPort (XNPT) Said FDA Moves PDUFA Date Due to February 11
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
Pro-Pharmaceuticals, Inc. (Amex: PRW) announced that the FDA has granted an Investigational New Drug application for use of DAVANAT in combination with chemotherapy and biologic to treat a breast cancer patient.
Pro-Pharmaceuticals currently has two ongoing Phase II clinical trials for first-line treatment of colorectal and biliary cancer patients. [LJ]
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
